Longeveron Inc. 8-K

What Happened Longeveron Inc. (filed May 8, 2026) announced that a Type C meeting with the U.S. Food and Drug Administration (FDA) was held in late March, with the FDA issuing a meeting summary in late April. The meeting discussed laromestrocel (LOMECEL‑B®), the Company’s allogeneic cell therapy being evaluated in the randomized, controlled Phase 2b ELPIS II trial for hypoplastic left heart syndrome (HLHS). Top-line ELPIS II results are expected in August 2026. The FDA said right ventricle ejection fraction (RVEF) is not an appropriate primary endpoint; because an NIH‑mandated interim analysis (to which Longeveron is blinded) occurred during the trial, the FDA indicated a new primary endpoint cannot be agreed while the trial is ongoing and the Agency no longer refers to ELPIS II as a “pivotal” study at this time.

Key Details

• Filing date: Current Report on Form 8‑K filed May 8, 2026; Type C meeting held in late March and FDA meeting summary provided in late April.
• Trial timing: Top-line Phase 2b ELPIS II results anticipated in August 2026.
• FDA feedback: RVEF deemed insufficient as a primary efficacy endpoint; only objective measures (all‑cause mortality, cardiac transplant‑free survival, event of cardiac transplantation, and well‑defined major adverse cardiac events) were identified as informative.
• Company actions: Longeveron is capturing those objective measures in ELPIS II and intends to submit a Sponsor Statistical Analysis Plan (SAP) with a composite primary endpoint and secondary endpoints for FDA review; FDA said it will meet again after study completion to discuss results and next steps.

Why It Matters For investors, the key takeaways are that the FDA challenged the trial’s originally discussed primary endpoint (RVEF) and, because of the NIH interim analysis and the trial’s ongoing status, would not treat ELPIS II as pivotal at this time. That affects the regulatory framing until the study is completed and results reviewed. On the positive side, Longeveron is collecting hard clinical endpoints the FDA identified and plans to submit a SAP and meet with the FDA after the August 2026 readout, and it remains optimistic about pursuing a Biologics License Application (BLA) following the top‑line results. The filing contains standard forward‑looking statement disclosures; no new financial results were reported.